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ABSTRACT
Hypersensitivity pneumonitis (HP) is an immune-mediated pulmonary disorder involving inflam-
mation of the lung interstitium, terminal bronchioles, and alveoli caused by the immune response
to the inhalation of an offending environmental airborne agent. It can manifest as exertional
dyspnea, fatigue, weight loss, and progressive respiratory failure if left untreated. Because of its
protean features, it can be misdiagnosed as other common obstructive lung conditions such as
asthma. If triggers are not avoided, it can progress to irreversible pulmonary fibrosis. In this article,
we present the case of a 51-year-old male who presented to our hospital with recurrent bouts of
dyspnea and cough, initially diagnosed as an asthma exacerbation. He received a final diagnosis
of HP after investigation of his workplace revealed airborne spores and surface molds from
multiple fungal species, serology revealed eosinophilia, and computed tomography showed
bronchiectasis. Avoidance of occupational exposure resulted in significant improvement of his
respiratory symptoms after two months.
Abbreviations: HP: Hypersensitivity pneumonitis
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1. Introduction
Hypersensitivity pneumonitis (HP) is an immune-
mediated pulmonary disorder affecting the lung inter-
stitium, alveoli and bronchioles. It is caused by repeated
inhalation and sensitization to a variety of environmen-
tal airborne antigens which may provoke an exagger-
ated immune response in the lung parenchyma of
susceptible individuals [1,2]. HP may present with
acute or subacute to chronic symptoms. Acute HP is
characterized by flu-like symptoms, including chills,
fever, sweating, myalgias, and headache that begin a
few hours after antigen exposure, and respiratory symp-
toms of cough, chest tightness, and dyspnea are fre-
quently noted [2]. Subacute and chronic HP may
manifest with an insidious onset of cough, exertional
dyspnea, fatigue, and weight loss that occur over several
weeks tomonths, and overmonths to years, respectively
[2]. Because the clinical presentation varies widely and
because the findings are non-specific, the disorder is
often initially misdiagnosed as a more common pul-
monary condition. Specifically, acute HP, with wheez-
ing and cough with response to steroid, is often initially
thought to be asthma or chronic obstructive pulmonary
disease (COPD), whereas chronic HP is often confused
with non-specific interstitial pneumonia, usual intersti-
tial pneumonia, or cryptogenic organizing pneumonia
[3]. Misdiagnosis may delay proper treatment of HP
and failure to identify offending antigens, which may in
worst case result in irreversible damage to the lungs.
2. Case presentation
A 51-year-old Caucasian male presented to the emer-
gency department of our hospital with a two-week
history of shortness of breath and disabling cough.
The cough was productive of thick, whitish sputum,
and was aggravated by exertion and exposure to cold
air. He reported a history of frequent ‘bronchitis’
episodes and chronic mild dyspnea for the past two
years, and was previously diagnosed with mild per-
sistent asthma. He had required short courses of oral
corticosteroids three times in the past 12 months, but
this was his first presentation to the hospital and he
had never been intubated. Pulmonary function tests
11 months prior had revealed a forced vital capacity
(FVC) of 4.38 L (103% predicted), a forced expiratory
volume in 1 second (FEV1) of 3.59 L (104% pre-
dicted), and a FEV1:FVC ratio of 82%. Symptoms
during this exacerbation were not alleviated with
inhaled albuterol and ipratropium bromide, and he
had been placed on cefuroxime five days prior for
acute bronchitis by his primary care physician. He
noted using his inhaler every two hours for the past
24 hours without relief. He denied any fever, sore
throat, fatigue, malaise, nausea, vomiting, weight
changes, or recent sick contacts. He reported a family
history of asthma in his mother and two daughters,
and asbestos-related lung malignancies in both of his
parents. There was no history of smoking or illicit
drug use. There was no personal history of asbestos
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exposure, immunodeficiency, lung malignancy, or
allergy to pollen, dust, or mites. He noted having a
pet dog for years, but no other animal or hobby
exposures. He was however employed at a workplace
with a large walk-in refrigerator for the past 15 years
and reported presence of considerable mold growth
in the coolers. He also noted that other colleagues
with exposure to the cooler had similar symptoms.
Although he denied any recent travel history, he
reported transient improvement of his dyspnea and
cough when he traveled to another state for a week
away from his job site.
On physical exam, he was afebrile and hemodyna-
mically stable. He had a resting oxygen saturation of
94% on room air, which initially declined to 87%
while ambulating. Pulmonary exam was notable for
high-pitched end-inspiratory wheezes throughout his
lungs and expiratory wheezes at his bases bilaterally.
Peak expiratory flow rate (PEFR) on admission was
550 L/min (weight-based expected PEFR is 545 L/
min), which increased to 775 L/min the following
morning after steroid administration.
Laboratory studies included the following: white
blood count (WBC): 5700/μL (4800–10 800/μL), with
18% eosinophils (normal: 0–6%), total eosinophil
count: 1030/μL (150–300/μL), total IgE: 440 IU/mL
(<154 IU/mL). Chest x-ray revealed non-enlarged,
asymmetric hilar opacities, but no acute cardiopul-
monary abnormalities (Figure 1(a)). Computed
tomography (CT) scan of the chest revealed mild
bronchitis with mucoid impaction in several bronchi
and several widened bronchi surrounded by inflam-
mation and positive signet ring sign suggesting mild
bronchiectasis (Figure 1(b)).
A preliminary admission diagnosis of asthma
exacerbation due to bronchitis was made due to
prior history of mild persistent asthma, and he was
started on prednisone, and nebulized albuterol and
ipratropium bromide. He showed mild improvement
within the next two days and was discharged home
on a tapered prednisone regimen and a possible dis-
charge diagnosis of allergic bronchopulmonary asper-
gillosis in the face of bronchiectasis, elevated IgE and
eosinophilia. However, serology for Aspergillus fumi-
gatus antibody and Aspergillus galactomannan anti-
gen were subsequently found to be negative. Local
health authorities were asked to investigate the
patient’s workplace, and they identified spores and
molds on surface samples within the coolers. Multiple
species were detected including Aspergillus,
Cladosporium, Nigrospora, and basidiospores. A
final diagnosis of HP was determined after the new
workplace safety findings of airborne spores and sur-
face molds. He was instructed to avoid the coolers at
his workplace, which were then sterilized. He
reported marked improvement in his symptoms
after two months, at which time the repeat
Aspergillus serology was found to again be negative,
as well as serology for Thermoactinomyces and
Micropolyspora.
3. Discussion
HP was first described in 1700 by Bernardino
Ramazzini, who observed shortness of breath and
cachexia in grain workers after repeated exposure to
grain dust [3]. However, the first detailed description
of HP appeared in 1932, after a study described
dyspnea, productive cough, night sweats, and weight
loss in workers who were stripping bark from maple
logs. Further investigation isolated the fungus
Cryptostroma corticale from the dust accompanying
the maple bark, and it was postulated that the work-
ers’ symptoms were due to an immune reaction to
airborne spores [4,5].
Despite decades of advances in our understanding
of HP, no universal disease definition yet exists [6,7].
Many experts describe HP as a disease that primarily
affects the lungs but may also include constitutional
symptoms including fever and weight loss. HP is
(a) (b)
Figure 1. (a) Chest x-ray shows non-enlarged but asymmetric hilar opacities. (b) Axial view demonstrates mild bronchitis with
mucoid impaction in several bronchi and several widened bronchi surrounded by inflammation and positive signet ring sign,
suggestive of mild bronchiectasis.
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believed to be caused by an offending airborne anti-
gen to which the host mounts an exaggerated
immune response. Symptoms typically appear or
worsen hours after antigen exposure. Studies propose
a ‘two-hit’ hypothesis to describe the development of
HP, stating that genetic susceptibility comprises the
‘first hit’ and increases the risk of HP after the ‘sec-
ond hit’ arrives in the form of antigen exposure [2].
Typically, these offending antigens originate from
occupational exposures, but may also come from
hobbies, recreational activities, and contaminated air
systems [4]. Over 300 etiologies of HP have been
reported [8,9] and have traditionally been divided
into three major antigen categories: microbes, pro-
teins from animals or plants, and low-molecular
weight chemicals. Avian proteins and microbial
agents comprise the most commonly reported causes
of HP [2,4,6]. Specific examples of diagnoses along
the HP spectrum are listed in Supplemental Table 1.
As it pertains to our case report, workers exposed to
ventilation systems and water-related contamination
(forced-air systems, humidifiers, whirlpools, spas)
may be exposed to antigens of various species includ-
ing Thermoactinomyces, Cladosporium, and
Mycobacterium avium [10,11].
A large epidemiological study reported an inci-
dence of HP of approximately 1 per 100 000 people
in the UK [12]. However, the exact prevalence of HP is
unknown given that cases often go undetected or are
misdiagnosed. In addition, there is no standardized
method to assess the disorder, given the lack of defined
diagnostic criteria and diagnostic modalities used [4].
Symptoms in HP have been conventionally classi-
fied into acute, subacute, and chronic-predominant
stages, but significant overlap is frequently noted
(Table 1) [2]. Acute HP is characterized by a rapid
onset of flu-like symptoms, including chills, fever,
sweating, myalgias, and headache that begin a few
hours after exposure, and usually involves cough,
chest tightness, and dyspnea [2]. Subacute and
chronic HP both manifest with an insidious onset of
cough, exertional dyspnea, fatigue, and weight loss.
One scheme differentiates the two: subacute disease
occurs over weeks to four months with episodic flare-
ups, while chronic disease occurs over four months to
years and consists of fibrosis, emphysema, or both
[4,13]. During symptomatic episodes, pulmonary
function tests (PFTs) typically show restrictive dis-
ease, but an obstructive pattern may also be present
[6]. Tachypnea, tachycardia, and bibasilar crackles are
often present on physical exam, and hypoxemia and
respiratory failure may occur in severe cases [4].
Chest radiograph and CT scan findings vary based
on stage of disease, with mostly nonspecific findings
[15]. Ground glass opacities are most common in
acute HP, and a reticulonodular pattern has been
inconsistently documented [7]. Radiographic findings
in subacute HP include ground glass opacities, cen-
trilobular nodules, and air trapping [7]. More consis-
tency is noted in imaging studies of chronic HP as
upper-lobe and middle-lobe predominance of fibrotic
changes, including reticular opacities and honey-
combing, are almost invariably present [6,7].
Additional findings in chronic HP may include irre-
gular subpleural linear opacifications, traction
bronchiectasis, air trapping, lobar volume loss, and
patchy emphysema [7]. Centrilobular nodules and
ground-glass attenuation have been noted to be
reversible in patients who avoid exposure to the
offending agent, although honeycombing and emphy-
sema usually indicate irreversible damage [16,17].
Notably, patients with chronic HP may have an
Table 1. Clinical features of hypersensitivity pneumonitis.
Category Acute Subacute Chronic
Clinical duration 4–48 hours Weeks to four months Four months to years
Symptoms Fever, chills, diaphoresis, cough,
chest tightness, dyspnea,
hypoxemia, generalized body
aches and myalgias, headache
Exertional dyspnea, cough, fatigue,
weight loss, episodic flares
Exertional dyspnea, cough, fatigue,
weight loss
Immuno-pathophysiology Alveolitis from neutrophilic
infiltration, immune complex
deposition with fibrin, tiny
granulomas
Classic histologic triad of subacute HP:
interstitial infiltrate, bronchiolitis,
formation of poorly-formed
granulomas. Triad is present in up to
75% of cases [14]. Interstitial infiltrate
is typically composed of plasma cells
and lymphocytes
Lymphocytic infiltration and fibrosis,
neutrophil-mediated destruction,
often includes eosinophil and mast
cell infiltration
High-resolution CT chest
findings
Ground glass opacities (most
common), reticulonodular
pattern, confluent alveolar
opacification
Ground glass opacities centrilobular
nodules, air trapping
Irregular subpleural linear
opacifications, traction
bronchiectasis, air trapping, lobar
volume loss, Interstitial fibrosis,
honeycombing pattern, patchy
emphysema
Prognosis Good Typically good Poor (especially with presence of
extensive fibrosis)
Treatment Avoidance of offending agent. Systemic corticosteroids if symptoms progress despite antigen avoidance. Lung
transplant in severe cases of chronic HP.
Symptoms, pathophysiology, natural history, and treatment are presented based on different stages of HP.
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imaging pattern similar to that of nonspecific inter-
stitial pneumonia (NSIP) or usual interstitial pneu-
monia (UIP) [7,18].
Bronchoalveolar lavage is a sensitive test to detect
alveolitis, with the most typical pattern showing a sig-
nificant lymphocyte-rich alveolitis (>20% of total cells
recovered, but more often >50%) [6,19,20]. In rare
cases, clinicians may pursue surgical transbronchial
biopsy to verify clinical diagnosis in patients refractory
to therapy [6]. Laboratory tests are neither sensitive nor
specific, but a mild leukocytosis, lymphocystosis, and
eosinophilia may be present in some cases [21,22].
Because diagnosis of HP is often challenging, a
clinical prediction model was developed by Lacasse
et al. to aid clinicians. Criteria include exposure to a
known offending antigen, positive precipitating anti-
bodies, recurrent symptomatic flares, inspiratory
crackles, symptoms that occur four-to-eight hours
after antigen exposure, and weight loss [21].
Interestingly, documenting exposure to a known
offending antigen alone has a high odds ratio of
38.8 [21]. The probability of HP is 98% in patients
who satisfy all six criteria in the model [6,21]. Our
case report patient satisfied only three criteria (expo-
sure to known antigen, recurrent symptoms, and
symptoms that occur soon after antigen exposure).
Although he did not have positive serologic testing, it
is important to note that the sensitivity and specificity
of serum-specific antibody testing is very low [23],
with one study citing a 25% detection rate in diag-
nosed HP patients [24]. Additional studies are needed
to validate this diagnostic prediction system, but it
offers promise towards more uniform, defined diag-
nostic criteria in the future.
Despite this initiative towards better prediction
models, diagnosis of HP remains difficult and may
be missed due to lack of specific clinical features and
awareness among health-care providers. The clinical
presentation and natural history are highly variable.
Many patients with mild or sub-clinical HP escape
detection or are misdiagnosed as suffering from viral
upper respiratory illness or asthma [25], either of
which may have nonspecific findings that mimic
HP. On the other end of the spectrum, severe sub-
acute and chronic HP may mimic interstitial lung
diseases such as usual interstitial pneumonia.
Misdiagnosis has critical therapeutic and prognostic
implications as it may delay proper treatment of HP,
and result in significant morbidity, unnecessary hos-
pitalizations, and irreversible fibrosis to the lungs.
Key discriminatory findings between asthma and
hypersensitivity in this case include normal spirome-
try, completely normal peak flow testing despite
ongoing symptoms, hypoxemia, significant eosino-
philia, elevated IgE level, and bronchiectatic changes
on imaging. Any one of these should make physicians
consider an alternative diagnosis [26].
Avoidance of exposure to the suspected or con-
firmed agent is the mainstay of HP management. If
HP continues to progress despite avoidance of anti-
gen exposure, treatment with systemic corticosteroids
is considered. In chronic HP, progressive pulmonary
fibrosis is typically irreversible and does not respond
to treatment [4]. In these cases, lung transplantation
may be considered [6]. Generally, patients with acute
or subacute HP without fibrotic changes have a good
prognosis as they respond well to avoidance of the
inciting exposure. However, once fibrosis occurs in
chronic HP, prognosis is not favorable [27].
4. Teaching points
(1) Diagnosis of HP is challenging due to lack of
specific clinical features, absence of universal
diagnostic criteria, low awareness among clin-
icians, and variable clinical presentation.
(2) Although HP is infrequent, it should always be
kept in the differential diagnosis of dyspnea
and cough, especially in a patient with a sus-
pected source of exposure to an offending
environmental agent, hypoxemia, eosinophilia,
and normal peak flows.
(3) HP may mimic viral upper respiratory illness or
asthma exacerbation. Misdiagnosis has critical
therapeutic and prognostic implications as it
may delay proper treatment of HP and result
in significant morbidity, unnecessary hospitali-
zations, and irreversible fibrosis to the lungs.
(4) HP can initially be treated conservatively with
avoidance of the offending agent. Some cases
of HP may require systemic corticosteroids
and consideration for lung transplantation if
severe fibrosis is present.
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